^
Association details:
| Biomarker: | EGFR L858R + EGFR L747V |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Durable response to afatinib rechallenge in a long-term survivor of non-small cell lung cancer harboring EGFR L858R and L747V mutations
Published date:
10/04/2022
Excerpt:
...we report a long-term (≥20 years from initial diagnosis) NSCLC survivor carrying EGFR L858R and L747V mutations….and responded to afatinib rechallenge with a progression-free survival of 12 months.
DOI:
https://doi.org/10.1111/1759-7714.14678
